Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial - Mamounas, E P; Bandos, H; Lembersky, B C (Lancet Oncol, 2019)